Myeloid-derived suppressor sells and the efficacy of CD8+ T-cell immunotherapy

OncoImmunology

Volumn 2, Issue 2, 2013, Pages

  Lesokhin, Alexander M ^a   Merghoub, Taha ^a   Wolchok, Jedd D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Adoptive T cell transfer; CCR2; GM CSF; Immunotherapy; Myeloid derived suppressor cells

Indexed keywords

CD11B ANTIGEN; CHEMOKINE RECEPTOR CCR2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IPILIMUMAB; MONOCYTE CHEMOTACTIC PROTEIN 1;

CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL PROLIFERATION; CLINICAL EFFECTIVENESS; HUMAN; IMMUNE EVASION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; MELANOMA; MONOCYTIC MYELOID DERIVED SUPPRESSOR CELL; NITROSYLATION; NONHUMAN; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; SUPPRESSOR CELL; TREATMENT OUTCOME; TUMOR ABLATION; TUMOR ESCAPE;

EID: 84886945666     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.22764     Document Type: Note

References (10)

1. Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 2006; 116:1935-1945; PMID:16778987; http://dx.doi.org/10.1172/JCI27745.
2. Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12:298-306; PMID:22419253; http://dx.doi.org/10.1038/nrc3245.
3. Lesokhin AM, Hohl TM, Kitano S, Cortez C, Hirschhorn-Cymerman D, Avogadri F, et al. Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res 2012; 72:876-886; PMID:22174368; http://dx.doi.org/10.1158/0008-5472.CAN-11-1792.
4. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162-74; PMID:19197294; http://dx.doi.org/10.1038/nri2506.
5. Bronte V, Chappell DB, Apolloni E, Cabrelle A, Wang M, Hwu P, et al. Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J Immunol 1999; 162:5728-5737; PMID:10229805.
6. Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 2007; 13:828-35; PMID:17603493; http://dx.doi.org/10.1038/nm1609.www.landesbioscience.com OncoImmunology e22764-e22763.
7. Molon B, Ugel S, Del Pozzo F, Soldani C, Zilio S, Avella D, et al. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J Exp Med 2011; 208:1949-e227662; PMID:21930770; http://dx.doi.org/10.1084/jem.20101956.
8. Montero AJ, Diaz-Montero CM, Kyriakopoulos CE, Bronte V, Mandruzzato S. Myeloid-derived suppressor cells in cancer patients: a clinical perspective. J Immunother 2012; 35:107-115; PMID:22306898; http://dx.doi.org/10.1097/CJI.0b013e318242169f.
9. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012; 366:925-931; PMID:22397654; http://dx.doi.org/10.1056/NEJMoa1112824.
10. Kitano S, Postow MA, Cortez C, et al. Myeloidderived suppressor cell quantity prior to treatment with ipilimumab at 10mg/kg to predict for overall survival in patients with metastatic melanoma. ASCO Annual Meeting.Vol. 30. Chicago, IL: J ClinOncol; 2012.